Career & Filing History
Every role Sarah Gheuens has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Sarah Gheuens is a corporate insider at Viridian Therapeutics, Inc.\DE (VRDN). Gheuens has also held reporting roles at AGIOS PHARMACEUTICALS, INC. (AGIO). Gheuens has reported 11 insider filings with the SEC since 2025. The most recent filing was in July 2026.
Every role Sarah Gheuens has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
AGIOS PHARMACEUTICALS, INC. (AGIO)3 filingsViridian Therapeutics, Inc.\DE (VRDN)1 filingUpdated Aug 30, 2026
Sarah Gheuens is Chief Medical Officer of AGIOS PHARMACEUTICALS, INC. (AGIO). 12 SEC Form 4 filings on record going back to 2025, most recently on 6 August 2026. Most recent open-market trade: sold $914K of AGIO on 6 August 2026. Lifetime open-market sales: $2.14M.
Every recent SEC Form 4 transaction Sarah Gheuens has reported, most recent first.
InsiderAlpha's records for Sarah Gheuens go back to 2025: 12 primary Form 4 filings, an average of 6.0 per year. 28 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Sarah Gheuens files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Sarah Gheuens is a corporate insider, tracked as Chief Medical Officer of AGIOS PHARMACEUTICALS, INC. (AGIO). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases and 12 open-market sales ($2.14M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial